These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 24152645)

  • 1. 99mTc-sestamibi using a direct conversion molecular breast imaging system to assess tumor response to neoadjuvant chemotherapy in women with locally advanced breast cancer.
    Mitchell D; Hruska CB; Boughey JC; Wahner-Roedler DL; Jones KN; Tortorelli C; Conners AL; O'Connor MK
    Clin Nucl Med; 2013 Dec; 38(12):949-56. PubMed ID: 24152645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of
    Hunt KN; Conners AL; Goetz MP; O'Connor MK; Suman V; Kalari K; Weinshilboum R; Wang L; Carter J; McLaughlin S; Aspitia AM; Gray R; Northfelt D; Boughey JC
    AJR Am J Roentgenol; 2019 Oct; 213(4):932-943. PubMed ID: 31166752
    [No Abstract]   [Full Text] [Related]  

  • 3. Is Technetium-99m Sestamibi Imaging Able to Predict Pathologic Nonresponse to Neoadjuvant Chemotherapy in Breast Cancer? A Meta-analysis Evaluating Current Use and Shortcomings.
    Collarino A; de Koster EJ; Valdés Olmos RA; de Geus-Oei LF; Pereira Arias-Bouda LM
    Clin Breast Cancer; 2018 Feb; 18(1):9-18. PubMed ID: 28728876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breast cancer: influence of tumour volume estimation method at MRI on prediction of pathological response to neoadjuvant chemotherapy.
    Henderson SA; Muhammad Gowdh N; Purdie CA; Jordan LB; Evans A; Brunton T; Thompson AM; Vinnicombe S
    Br J Radiol; 2018 Jul; 91(1087):20180123. PubMed ID: 29641224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of molecular breast imaging to assess response in women undergoing neoadjuvant therapy for breast cancer: a pilot study.
    Wahner-Roedler DL; Boughey JC; Hruska CB; Chen B; Rhodes DJ; Tortorelli CL; Maxwell RW; Cha SS; O'Connor MK
    Clin Nucl Med; 2012 Apr; 37(4):344-50. PubMed ID: 22391702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive value of PET-CT for pathological response in stages II and III breast cancer patients following neoadjuvant chemotherapy with docetaxel.
    García García-Esquinas MA; Arrazola García J; García-Sáenz JA; Furió-Bacete V; Fuentes Ferrer ME; Ortega Candil A; Cabrera Martín MN; Carreras Delgado JL
    Rev Esp Med Nucl Imagen Mol; 2014; 33(1):14-21. PubMed ID: 23809513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer.
    Ciarmiello A; Del Vecchio S; Silvestro P; Potena MI; Carriero MV; Thomas R; Botti G; D'Aiuto G; Salvatore M
    J Clin Oncol; 1998 May; 16(5):1677-83. PubMed ID: 9586878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Near-Infrared Spectral Tomography for Predicting Residual Cancer Burden during Early-Stage Neoadjuvant Chemotherapy for Breast Cancer.
    Cao X; Muller KE; Chamberlin MD; Gui J; Kaufman PA; Schwartz GN; diFlorio-Alexander RM; Pogue BW; Paulsen KD; Jiang S
    Clin Cancer Res; 2023 Dec; 29(23):4822-4829. PubMed ID: 37733788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of Residual Disease With Molecular Breast Imaging in Patients Undergoing Neoadjuvant Therapy: Association With Molecular Subtypes.
    Menes TS; Golan O; Vainer G; Lerman H; Schneebaum S; Klausner J; Even-Sapir E
    Clin Breast Cancer; 2016 Oct; 16(5):389-395. PubMed ID: 27282845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor-infiltrating lymphocytes and residual cancer burden.
    Asano Y; Kashiwagi S; Goto W; Takada K; Takahashi K; Hatano T; Noda S; Takashima T; Onoda N; Tomita S; Motomura H; Ohsawa M; Hirakawa K; Ohira M
    BMC Cancer; 2017 Dec; 17(1):888. PubMed ID: 29282021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Prognostic Impact of Early Change in 18F-FDG PET SUV After Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer.
    Lee HW; Lee HM; Choi SE; Yoo H; Ahn SG; Lee MK; Jeong J; Jung WH
    J Nucl Med; 2016 Aug; 57(8):1183-8. PubMed ID: 27033896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of (99m)Tc-sestamibi washout in predicting response of locally advanced breast cancer to neoadjuvant chemotherapy.
    Sciuto R; Pasqualoni R; Bergomi S; Petrilli G; Vici P; Belli F; Botti C; Mottolese M; Maini CL
    J Nucl Med; 2002 Jun; 43(6):745-51. PubMed ID: 12050317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Machine Learning With Multiparametric Magnetic Resonance Imaging of the Breast for Early Prediction of Response to Neoadjuvant Chemotherapy and Survival Outcomes in Breast Cancer Patients.
    Tahmassebi A; Wengert GJ; Helbich TH; Bago-Horvath Z; Alaei S; Bartsch R; Dubsky P; Baltzer P; Clauser P; Kapetas P; Morris EA; Meyer-Baese A; Pinker K
    Invest Radiol; 2019 Feb; 54(2):110-117. PubMed ID: 30358693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interim heterogeneity changes measured using entropy texture features on T2-weighted MRI at 3.0 T are associated with pathological response to neoadjuvant chemotherapy in primary breast cancer.
    Henderson S; Purdie C; Michie C; Evans A; Lerski R; Johnston M; Vinnicombe S; Thompson AM
    Eur Radiol; 2017 Nov; 27(11):4602-4611. PubMed ID: 28523352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of molecular breast imaging in predicting complete tumor response to treatment and residual tumor extent following neoadjuvant therapy.
    Nuvoli S; Galassi S; Gelo I; Rocchitta G; Fancellu A; Serra PA; Madeddu G; Spanu A
    Oncol Rep; 2018 May; 39(5):2055-2062. PubMed ID: 29512735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diffuse optical tomography changes correlate with residual cancer burden after neoadjuvant chemotherapy in breast cancer patients.
    Lim EA; Gunther JE; Kim HK; Flexman M; Hibshoosh H; Crew K; Taback B; Campbell J; Kalinsky K; Hielscher A; Hershman DL
    Breast Cancer Res Treat; 2017 Apr; 162(3):533-540. PubMed ID: 28190249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Value of 18F-FDG PET/CT for early prediction of pathologic response (by residual cancer burden criteria) of locally advanced breast cancer to neoadjuvant chemotherapy.
    Lee SM; Bae SK; Kim TH; Yoon HK; Jung SJ; Park JS; Kim CK
    Clin Nucl Med; 2014 Oct; 39(10):882-6. PubMed ID: 25072926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Residual tumor uptake of [99mTc]-sestamibi after neoadjuvant chemotherapy for locally advanced breast carcinoma predicts survival.
    Dunnwald LK; Gralow JR; Ellis GK; Livingston RB; Linden HM; Lawton TJ; Barlow WE; Schubert EK; Mankoff DA
    Cancer; 2005 Feb; 103(4):680-8. PubMed ID: 15637688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective Evaluation of Ultrafast Breast MRI for Predicting Pathologic Response after Neoadjuvant Therapies.
    Ramtohul T; Tescher C; Vaflard P; Cyrta J; Girard N; Malhaire C; Tardivon A
    Radiology; 2022 Dec; 305(3):565-574. PubMed ID: 35880977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deep Learning-Based Segmentation of Locally Advanced Breast Cancer on MRI in Relation to Residual Cancer Burden: A Multi-Institutional Cohort Study.
    Janse MHA; Janssen LM; van der Velden BHM; Moman MR; Wolters-van der Ben EJM; Kock MCJM; Viergever MA; van Diest PJ; Gilhuijs KGA
    J Magn Reson Imaging; 2023 Dec; 58(6):1739-1749. PubMed ID: 36928988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.